MedTrace Logo

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03080051 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-10-06

No results posted yet for this study

Summary

The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.

Conditions

Interventions

DRUG

[18F]MNI-952

Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.

DRUG

[18F]Florbetapir

Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.

Sponsors & Collaborators

  • Molecular NeuroImaging

    lead OTHER

Principal Investigators

  • Jennifer Madonia, PA-C · Molecular NeuroImaging

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-03-06
Completion
2017-03-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03080051 on ClinicalTrials.gov